AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)

Who is this study for? Adult patients with atrial fibrillation
What treatments are being studied? Apixaban
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

There has no evidence for the anticoagulation in patients who had undergone catheter ablation of atrial fibrillation, and has maintained sinus rhythm for more than 1 year. However, anticoagulation can increase the risk of bleeding, the study evaluating the role of oral anticoagulation is needed in this patients. This study will compare the efficacy and safety of non-vitamin K anticoagulants (apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Maximum Age: 80
Healthy Volunteers: f
View:

• no recurrence of atrial fibrillation one year after catheter ablation of atrial fibrillation

• CHA2DS2-VASc score \>=1 (male) or \>=2 (female)

• age: 19 to 80 years

• non-valvular atrial fibrillation

• those who consent the study.

• those who can be followed after enrollment

Locations
Other Locations
Republic of Korea
Severance Cardiovascular Hospital Yonsei University
RECRUITING
Seoul
Contact Information
Primary
Boyoung Joung, Ph.D
cby6908@yuhs.ac
82-2-2228-8447
Time Frame
Start Date: 2020-07-28
Estimated Completion Date: 2028-10
Participants
Target number of participants: 840
Treatments
Experimental: Anticoagulation group(Apixaban group)
Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
No_intervention: Nonanticoagulation group
Standard treatment except anticoagulant for 2 years
Sponsors
Leads: Yonsei University

This content was sourced from clinicaltrials.gov